Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Nordic Nanovector gains access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment.
Lead Product(s): Radioimmunoconjugate-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Nordic Nanovector
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 06, 2023